» Articles » PMID: 28978076

Cancer Antigen 15-3, Platelet Distribution Width, and Fibrinogen in Combination to Distinguish Breast Cancer from Benign Breast Disease in Non-conclusive Mammography Patients

Overview
Journal Oncotarget
Specialty Oncology
Date 2017 Oct 6
PMID 28978076
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females. However, mammographic diagnosis is sometimes non-conclusive with a Breast imaging Reporting and Data System (Bi-RaDS) result of 0. Cancer antigen 15-3 (CA15-3) is the most widely used serum tumor marker for breast cancer screening. Platelet distribution width (PDW) is an early indicator of platelet activation. Fibrinogen contributed to angiogenesis and distant metastasis. The aim of this study was to investigate the ability of CA15-3, PDW, and fibrinogen individually or in combination, to distinguish breast cancer from benign breast disease. 200 consecutive patients with breast cancer and 187 patients with benign breast disease were included in this retrospective study. Patients' characteristics and hematologic tests data at initial diagnosis were collected. The benefit of adding PDW and fibrinogen to a model with only CA15-3 was evaluated as an increased in the area under the curve (AUC) obtained by receiver operating curve (ROC). CA15-3, PDW and fibrinogen are higher in breast cancer patients than in patients with benign breast disease. Single biomarkers had AUC values ranging from 0.687 for fibrinogen to 0.810 for CA15-3. In addition, the combination of PDW, CA15-3, and fibrinogen increased the AUC to 0.900 (0.866-0.928) (p<0.0001), significantly higher than those of any single marker. In conclusion, the combined use of CA15-3, PDW and fibrinogen may be clinically useful in discriminating between breast cancer and benign breast disease in non-conclusive mammography patients.

Citing Articles

Neutrophil Extracellular Traps Enhance Procoagulant Activity and Predict Poor Prognosis in Patients With Metastatic Breast Cancer.

Gong Y, Chen B, Tan Q, Wei W Int J Gen Med. 2025; 18:1247-1259.

PMID: 40062357 PMC: 11890004. DOI: 10.2147/IJGM.S511024.


A Coagulation-Related Gene-Based Prognostic Model for Invasive Ductal Carcinoma.

Li J, Du J, Wang Y, Jia H Front Genet. 2021; 12:722992.

PMID: 34621293 PMC: 8490773. DOI: 10.3389/fgene.2021.722992.


Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer.

Giaccherini C, Marchetti M, Masci G, Verzeroli C, Russo L, Celio L Haematologica. 2019; 105(6):1704-1711.

PMID: 31558668 PMC: 7271573. DOI: 10.3324/haematol.2019.228981.


Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer.

Kirwan C, Descamps T, Castle J Clin Transl Oncol. 2019; 22(6):870-877.

PMID: 31473984 PMC: 7188731. DOI: 10.1007/s12094-019-02197-6.

References
1.
Kilincalp S, Ekiz F, Basar O, Ayte M, Coban S, Yilmaz B . Mean platelet volume could be possible biomarker in early diagnosis and monitoring of gastric cancer. Platelets. 2013; 25(8):592-4. DOI: 10.3109/09537104.2013.783689. View

2.
Toth B, Liebhardt S, Steinig K, Ditsch N, Rank A, Bauerfeind I . Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost. 2008; 100(4):663-9. View

3.
Yu W, Wang Y, Shen B . An elevated preoperative plasma fibrinogen level is associated with poor overall survival in Chinese gastric cancer patients. Cancer Epidemiol. 2016; 42:39-45. DOI: 10.1016/j.canep.2016.03.004. View

4.
Lin R, Afshar-Kharghan V, Schafer A . Paraneoplastic thrombocytosis: the secrets of tumor self-promotion. Blood. 2014; 124(2):184-7. PMC: 4093679. DOI: 10.1182/blood-2014-03-562538. View

5.
Kumari N, Dwarakanath B, Das A, Bhatt A . Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016; 37(9):11553-11572. DOI: 10.1007/s13277-016-5098-7. View